References
- L. Cheong, P. Heng, and L. Wong.(1992). Relationship between polymer viscosity and drug release from a matrix system Pharm. Res 9:1510–1514.
- R. Dedrick, C. Meyers, P. Bungay, and V. DevitaJr..(1978). Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat. Rep 62:1–9.
- I. Fidler, and I. Hart.(1982). Biological diversity in metastatic neoplasms: origin and implications Science 217:998–1003.
- I. Fidler.(1985). Macrophages and metastasis—a biological approach to cancer therapy: presidential address Cancer Res 45:4714–4726.
- A. Hagiwara, T. Takahashi, T. Ueda, A. Iwamoto, and T. Torii.(1987). Activated carbon particles as anti‐cancer drug carrier into regional lymph nodes Anti‐cancer Drug Design 1:313–321.
- A. Hagiwara, T. Takahashi, M. Lee, C. Sakakura, S. Shoubayashi, S. Tashima, A. Yamamoto, and S. Muranishi.(1993). Selective delivery of etoposide to intraperitoneal tissues using a new dosage format: etoposide microcrystals suspended in oil Anti‐Cancer Drugs 4:27–31.
- J. HibbsJr., L. LambertJr., and J. Remington.(1972). Control of carcinogenesis: a possible role for the activated macrophages Science 177:998–1000.
- T. Kakutani, K. Yamaoka, M. Hashida, and H. Sezaki.(1985). A new method of assessment of drug disposition in muscle: application of statistical moment theory to local perfusion system J. Pharmacokinet. Biopharm 13:609–613.
- J. Lee, T. Takahashi, A. Hagiwara, C. Yoneyama, M. Itoh, T. Sasabe, S. Muranishi, and S. Tashima.(1995). Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis Cancer Chemother. Pharmacol 36:211–216.
- V. Levin.(1986). Clinical anticancer pharmacology: some pharmacokinetic considerations Cancer Treat. Rev 13:61–76.
- C. Litterst, I. Torres, McGunagle Arnold, D. Furner, B. Sikic, and A. Guarino.(1982). Absorption of antineoplastic drugs following large‐volume i.p. administration to rats Cancer Treat. Rep 66:147–155.
- G. Lukas, S. Brindle, and P. Greengard.(1990). The route of absorption intraperitoneally administered compounds J. Pharmacol. Exp. Ther 178:562–566.
- M. Meyer, and D. Guttman.(1970). Dynamic dialysis as a method for studying protein binding I: factors affecting the kinetics of dialysis through a cellophane membrane J. Pharm. Sci 59:33–38.
- S. Miyazaki, N. Hashiguchi, M. Sugiyama, M. Takada, and Y. Morimoto.(1986a). Fibrinogen microspheres as novel drug delivery systems for antitumor drugs Chem. Pharm. Bull 34:1370–1375.
- S. Miyazaki, N. Hashiguchi, W. Hou, C. Yokouchi, and M. Takada.(1986b). Antitumor effect of fibrinogen microparticles containing Adriamycin on Ehrlich ascites carcinoma in mice Chem. Pharm. Bull 34:2632–2636.
- E. Nara, M. Masegi, T. Hatono, and M. Hashida.(1992). Pharmacokinetic analysis of drug absorption from muscle based on a physiological diffusion model: effect of macromolecular size on absorption Pharm. Res 9:161–168.
- G. Nicolson.(1984). Cell surface molecules and tumor metastasis: regulation of metastatic phenotypic diversity Exp. Cell Res 150:3–22.
- S. Ozawa, Y. Sugiyama, and Y. Mitsuhashi.(1989). Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells Cancer Res 49:3823–3828.
- H. Sezaki, and M. Hashida.(1984). Macromolecule‐drug conjugates in targeted cancer chemotherapy CRC Crit. Rev. Ther. Drug Carrier Syst 1:1–38.
- H. Sezaki, Y. Takakura, and M. Hashida.(1989). Soluble macromolecular carriers for the delivery of antitumor drugs Adv. Drug Delivery Rev 3:247–266.
- Y. Tabata, and Y. Ikada.(1990a). Drug delivery systems for antitumor activation of macrophages Crit. Rev. Ther. Drug Carrier Syst 7:121–148.
- Y. Tabata, and Y. Ikada.(1990b). Macrophage activation for antitumor function by muramyl dipeptide‐protein conjugates J. Pharm. Pharmcol 42:13–19.
- Y. Yamaoka, T. Nakagawa, and T. Uno.(1978). Statistical moments in pharmacokinetics J. Pharmacokinet. Biopharm 6:547–558.